Latest Breaking News On - Tiffany aldrich - Page 1 : comparemela.com

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

ANN ARBOR, Mich., May 20, 2024 Esperion and Otsuka Pharmaceutical Co., Ltd announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Reports First Quarter 2024 Financial Results

– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents.

Esperion to Participate in Upcoming May Investor

ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following.